Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | IDO1 | P14902 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838502 | 1.00 | KMT2A (0.62) | KMT2AMEN1MAPTIDO1SIGMAR1 | |
| SCHEMBL17779151 | 0.87 | KMT2A (0.64) | KMT2AMEN1MAPTIDO1SIGMAR1 | |
| SCHEMBL3981844 | 0.87 | MAPT (0.50) | KMT2AMEN1MAPTIDO1SIGMAR1 | |
| SCHEMBL3424429 | 0.86 | POLB (0.54) | KMT2AMEN1MAPTIDO1SIGMAR1 | |
| SCHEMBL30557433 | 0.85 | MAPT (0.81) | KMT2AMEN1MAPTIDO1CYP1A2 | |
| SCHEMBL3822948 | 0.85 | MAPT (0.81) | KMT2AMEN1MAPTIDO1CYP1A2 | |
| SCHEMBL23220318 | 0.83 | IDO1 (0.68) | KMT2AMEN1MAPTIDO1ALDH1A1 | |
| SCHEMBL28151171 | 0.83 | MAPT (0.63) | KMT2AMEN1MAPTIDO1SIGMAR1 | |
| SCHEMBL4092320 | 0.83 | HPGD (0.53) | KMT2AMEN1MAPTIDO1SIGMAR1 | |
| SCHEMBL1185724 | 0.82 | SIGMAR1 (0.62) | KMT2AMEN1MAPTIDO1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630515-B2 | Small molecule prostagladin transport inhibitors | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4054608-B1 | SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250051314-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | PARIS SCIENCES ET LETTRES (FR) | 2025-02-13 | — | — | US | disclosed |
| EP-4444308-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | Institut Curie (FR) | 2024-10-16 | — | — | EP | disclosed |
| US-20240199561-A1 | INHIBITORS OF DYRK AND PIM | COLD SPRING HARBOR LABORATORY (US) | 2024-06-20 | — | — | US | disclosed |
| CN-112533967-B | Oil-in-water droplet type emulsion of active energy ray-curable resin composition and thermosensitive recording material | 日本化药株式会社 | 2023-09-15 | — | — | CN | disclosed |
| CN-114249702-B | N-aryl- [2,4 '-dithiazole ] -2' -amine compound and preparation and application thereof | 沈阳药科大学 | 2023-09-05 | — | — | CN | disclosed |
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| WO-2023104976-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | INSTITUT CURIE (FR) | 2023-06-15 | — | — | WO | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| US-4775677-A | ANTIALLERGNES, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1988-10-04 | — | — | US | disclosed |
| US-4491587-A | ANTIALLERGENS, ANTIHISTAMINES, MUSCLE RELAXANTS/ INSULATING POWDER BLANKET ABOVD THE MELT WITH HEAT GENERATED IN THE MELT BY ELECTRIC CURRENT; LOWER TEMPERATURE | MEAD JOHNSON & COMPANY (US) | 1985-01-01 | — | — | US | disclosed |
| US-4223031-A | ANTIALLERGENS, ANTIHISTAMINES, BRONCHODILATOR AGENTS, HYPERSENSITIVITY | MEAD JOHNSON & COMPANY (US) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | KMT2A 2992/4885MEN1 2168/4885MAPT 3492/4885 |
| US-20250051314-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | STAT1, IFNG, IRF2BP2 | KMT2A 2840/4885MEN1 3227/4885MAPT 4087/4885 |
| US-20240199561-A1 | INHIBITORS OF DYRK AND PIM | PIM3, PIM2, PIM1 | KMT2A 1849/4885MEN1 4519/4885MAPT 4414/4885 |
| US-12630515-B2 | Small molecule prostagladin transport inhibitors | PTGER1, PTGS1, PTGIR | KMT2A 4139/4885MEN1 4015/4885MAPT 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.